Oral GLP-1 for Weight Loss in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs VK2735

What is the Wegovy Pill?

The Wegovy pill is a once-daily oral semaglutide 25 mg tablet for chronic weight management, building on the oral semaglutide platform first introduced with Rybelsus for type 2 diabetes. Novo Nordisk announced FDA approval on December 22, 2025. The company’s 2025 annual report and February 2026 investor materials confirm US launch in January 2026. In its first launch quarter the Wegovy pill booked DKK 2.26 billion in sales (Novo Nordisk Q1 2026, May 6, 2026) — the first hard commercial proof point that an oral GLP-1 can scale revenue, not just trial data.

Novo reports that oral semaglutide 25 mg delivered 16.6% mean weight loss in OASIS 4 when treatment was adhered to, which the company describes as on par with injectable semaglutide 2.4 mg. The Wegovy pill and Foundayo (orforglipron) are now the two FDA-approved benchmarks against which any investigational oral obesity drug is compared. The decision framework below provides a structured approach to evaluating these candidates.

What is Foundayo (Orforglipron)?

Foundayo (orforglipron) is Eli Lilly’s once-daily oral non-peptide GLP-1 receptor agonist — the first non-peptide small-molecule GLP-1 in pill form on the U.S. market. The non-peptide structure is what enables the dosing-window difference: Foundayo can be taken any time of day, with or without food and water, while peptide-based oral semaglutide tablets (Rybelsus, the Wegovy pill) need the SNAC empty-stomach window. Our retatrutide vs orforglipron comparison examines how Lilly’s oral and injectable programmes relate.

In August 2025, Lilly reported positive Phase 3 obesity data from ATTAIN-1: the highest tested dose (36 mg) lowered body weight by an average of 14.3% at 72 weeks versus 2.1% for placebo. The FDA-approved label caps maintenance at 17.2 mg with ~12.4% mean weight loss at 72 weeks.

Foundayo was FDA-approved on April 1, 2026, cleared under the Commissioner’s National Priority Voucher pilot program 50 days after filing — the fastest approval of a new molecular entity since 2002. The Emirates Drug Establishment approved Foundayo in early April 2026 — the second country in the world to approve it — with patient availability in the UAE from May 2026.

A key supporting readout: ATTAIN-MAINTAIN (Aronne et al, Nat Med, May 12, 2026) showed orforglipron preserved 74.7% of weight loss in patients previously on tirzepatide and 79.3% in patients previously on semaglutide, over 52 weeks after switching off injectable GLP-1s — the first Phase 3 evidence that an oral GLP-1 can hold the line after stopping injectables.

What is Oral VK2735?

Oral VK2735 is Viking Therapeutics’ oral dual GIP/GLP-1 receptor agonist. In August 2025, Viking reported positive Phase 2 top-line data from VENTURE-Oral: oral VK2735 produced up to 12.2% mean weight loss after only 13 weeks versus 1.3% for placebo. The subcutaneous VK2735 Phase 3 programme has since moved ahead: VANQUISH-2 completed enrollment on March 26, 2026, and VANQUISH-1 was fully enrolled per Viking’s Q1 2026 report (April 29, 2026). Both Phase 3 readouts are expected in 2027.

The clinical interest is straightforward: if a 13-week oral dataset already exceeds 12% mean weight loss, the question is what longer-duration data will show. The caveat is equally clear—this is a much shorter study than Wegovy pill or orforglipron datasets, making direct comparisons premature. For UAE supplier verification around retatrutide research procurement, see our best retatrutide supplier Dubai guide.

Oral VK2735 is investigational and not approved. Track all upcoming regulatory milestones on our obesity drug approval tracker for 2026.

Which Oral Obesity Drug Matters Most Right Now?

The answer depends on the question. What can patients access today? Wegovy pill—the only approved oral GLP-1 for chronic weight management in the US. Which late-stage drug is most likely to reshape competition next? Orforglipron—positive Phase 3 data, regulatory review underway. Which earlier-stage asset has the biggest upside-watch factor? Oral VK2735—striking short-duration data, Phase 3 on the horizon. For injectable context, our retatrutide vs tirzepatide vs CagriSema comparison shows how far ahead injectables remain.

What About Oral Amycretin?

Oral amycretin (also referred to as zenagamtide in some contexts) is Novo Nordisk’s unimolecular GLP-1/amylin dual agonist in oral form. It is in Phase 2 development with limited publicly available data.

The amycretin concept is noteworthy because it combines two distinct mechanisms — GLP-1 and amylin receptor agonism — in a single molecule. This is structurally different from orforglipron (GLP-1 only) and oral VK2735 (GLP-1/GIP). If the oral formulation delivers efficacy comparable to the injectable version, it could represent a meaningful advance. But it is too early to assess — the compound is years behind both the Wegovy pill and orforglipron in clinical development.

Why Was Danuglipron Discontinued?

Pfizer discontinued danuglipron in 2024 due to tolerability issues. The oral GLP-1 agonist demonstrated meaningful weight loss in trials, but gastrointestinal side effects made it uncompetitive with other oral candidates that showed better tolerability profiles. Its discontinuation underscores that not every oral obesity drug candidate reaches the market — a reminder that positive Phase 2 efficacy data does not guarantee commercial viability.

Weight Loss Medications & Oral Obesity Drugs — The 2026 Landscape

Oral obesity drugs represent the next frontier in weight loss medications. For decades, obesity treatment relied on injectable GLP-1s, bariatric surgery, or older oral medications with modest efficacy. The arrival of oral formulations that rival injectable weight loss drugs in potency has reshaped the obesity market. Patients and clinicians now have multiple obesity medications under development that target GLP-1 receptors, GIP receptors, or both—all delivered as a daily pill or new pills in advanced clinical trials.

Why Oral Formulations Are Reshaping the Obesity Market

The obesity market has historically been dominated by weekly injection regimens. Many patients who need to lose weight prefer oral medications over injections, and the demand for oral obesity drugs is at an all-time high. Oral formulations remove barriers to adherence—no needles, no cold-chain storage, and integration into existing daily-pill routines. This shift is driving pharmaceutical companies to invest heavily in oral obesity medications, with several oral formulations now advancing through clinical trials simultaneously.

How GLP-1s Work as Weight Loss Medications

GLP-1s (glucagon-like peptide-1 receptor agonists) reduce appetite, slow gastric emptying, and enhance satiety signalling. As weight loss medications, GLP-1s help patients lose weight by acting on GLP-1 receptor pathways in the brain and gut. The GLP-1 receptor is the primary pharmacological target for both injectable and oral obesity drugs. Newer compounds like the retatrutide approval-status tracker add GIP receptor agonism and glucagon receptor engagement to produce greater weight loss than GLP-1-only obesity medications.

Clinical Trials & Trial Data for Oral Obesity Drugs

Clinical trials are the evidence backbone for every oral obesity drug seeking regulatory approval. As of 2026, the three leading candidates—Wegovy pill, orforglipron, and oral VK2735—have each produced clinical trial data from large, placebo-controlled studies. However, comparing clinical trial results across compounds is complicated by differences in study duration, patient populations, and statistical estimands. Patients enrolled in obesity clinical trials typically have a body mass index of 30 or above, or 27 with at least one weight-related comorbidity.

Key Clinical Trial Results Across Compounds

The OASIS programme (Wegovy pill) enrolled thousands of patients across multiple clinical trials evaluating oral semaglutide 25 mg for obesity. Eli Lilly’s ATTAIN programme generated clinical trial results for orforglipron across patients with obesity and type 2 diabetes. Viking Therapeutics’ VENTURE-Oral trial produced preliminary results in a shorter Phase 2 format. Each programme represents a different stage of clinical development, and clinical trial data from these studies collectively shapes the competitive landscape for oral obesity drugs in 2026.

Understanding Clinical Practice Implications

Clinical practice guidelines from major obesity medicine organisations increasingly recognise pharmacotherapy as a core pillar of obesity treatment. As clinical trial results translate into real-world clinical practice, clinicians must weigh efficacy, tolerability, cost, and patient preference when selecting among obesity medications. The availability of oral formulations expands the treatment toolkit for patients who previously declined injectable weight loss medications.

Obesity Treatment Beyond Weight Loss — Cardiovascular, Liver & Metabolic Benefits

Modern obesity treatment extends far beyond the scale. GLP-1-based obesity medications have demonstrated benefits for cardiovascular disease risk reduction, liver fat clearance, and metabolic health improvement. These broader health benefits are increasingly central to how clinicians and patients evaluate oral obesity drugs.

Major Adverse Cardiovascular Events (MACE) Data

Semaglutide (the active ingredient in Wegovy pill) demonstrated a 20% reduction in major adverse cardiovascular events in the SELECT trial—a landmark result for obesity medications. Major adverse cardiovascular events include heart attack, stroke, and cardiovascular death. This cardiovascular disease benefit is specific to semaglutide; orforglipron and oral VK2735 have not yet completed dedicated MACE outcome trials. Heart failure outcomes are also under investigation, as obesity is a major risk factor for heart failure.

Liver Fat Reduction & MASH-Related Outcomes

Obesity is closely linked to non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). GLP-1-based obesity medications have shown reductions in liver fat across clinical trials. Dual-agonist compounds like VK2735 may offer additional liver fat reduction through glucagon receptor activity, though this remains under investigation in clinical trials for oral obesity drugs.

Heart Failure, High Blood Pressure & Overall Health

Beyond major adverse cardiovascular events, oral obesity drugs may improve heart failure markers, reduce high blood pressure, and support overall health in patients with obesity. Weight loss of 10–15% is associated with clinically meaningful improvements in blood pressure, glycaemic control, and chronic disease burden. These benefits position oral obesity medications as treatments for the systemic consequences of obesity, not merely agents that help patients lose weight.

Obesity Care, Insurance Coverage & Patient Access

Obesity care in 2026 faces a fundamental access challenge. Even as highly effective obesity medications reach the market, insurance coverage remains inconsistent across countries and health systems. In the United States, Medicare does not cover most obesity medications, and many private insurers impose step therapy or prior authorisation requirements. The high demand for GLP-1-based weight loss medications has created supply constraints, further limiting patient access to obesity treatment.

Insurance Coverage for Oral Obesity Drugs

Insurance coverage is a critical barrier for patients seeking obesity medications. Without insurance coverage, the out-of-pocket cost of oral obesity drugs can exceed several hundred dollars per month. Policymakers and obesity medicine advocates argue that broader insurance coverage for obesity medications would reduce downstream costs from chronic diseases like type 2 diabetes, cardiovascular disease, and obstructive sleep apnea. As new oral obesity drugs enter the market, the insurance coverage landscape is expected to evolve.

Obesity Medicine & Clinical Practice Guidance

Obesity medicine is a rapidly growing specialty. Organisations such as the Obesity Medicine Association (OMA) and the European Association for the Study of Obesity (EASO) now publish clinical practice guidelines that incorporate oral obesity drugs. Obesity care increasingly emphasises a combined approach that pairs pharmacotherapy with lifestyle modification, psychological support, and long-term management. Harvard Medical School obesity researchers have published extensively on the evolving role of GLP-1s in obesity care and clinical practice.

Body Weight, Body Composition & Muscle Mass Considerations

Oral obesity drugs produce substantial reductions in body weight, but body composition changes matter as much as scale weight. Patients taking weight loss medications typically lose a combination of fat mass and lean mass. Preserving muscle mass during pharmacological obesity treatment is an active area of research and clinical concern.

Excess Weight, BMI & Waist Circumference

Clinical trials for oral obesity drugs measure efficacy using multiple endpoints: percentage body weight loss, absolute body weight reduction, proportion of patients achieving 5%, 10%, or 15% weight loss thresholds, and changes in body mass index and waist circumference. Patients with excess weight who lose 10% or more of body weight consistently show improvements in metabolic health markers. Waist circumference reduction is particularly meaningful because visceral fat drives much of the metabolic risk associated with obesity.

Muscle Mass, Muscle Loss & Strength Training

Muscle loss is a concern with all weight loss medications, including oral obesity drugs. Clinical trial data suggest that 20–40% of total weight lost during GLP-1 therapy may come from lean mass, though this varies across compounds and patient populations. Experts recommend strength training alongside obesity medications to preserve muscle mass and maintain metabolic rate. Strategies to preserve muscle mass—including adequate protein intake and resistance exercise—are increasingly incorporated into obesity treatment protocols.

GLP-1s & Substance Use Disorders — Emerging Research

One of the most unexpected findings in obesity research is the potential link between GLP-1s and substance use disorders. Preclinical and observational data suggest that GLP-1 receptor agonists may reduce addictive behaviours related to alcohol, nicotine, and other substance use disorders. Researchers at Harvard Medical School and other institutions have proposed that GLP-1s modulate reward systems in the brain, which may explain these broadly effective properties beyond obesity treatment.

Reward Systems & Broadly Effective Mechanisms

The GLP-1 receptor is expressed in brain regions involved in reward processing, including the nucleus accumbens and ventral tegmental area. GLP-1s appear to dampen reward systems that drive compulsive eating, substance use disorders, and other addictive behaviours. If ongoing clinical trials confirm these broadly effective mechanisms, GLP-1-based obesity medications could be repositioned for a much wider range of conditions—making them among the most broadly effective drug classes in modern medicine. Harvard Medical School researchers are leading several of these investigations.

Treating Diabetes, Chronic Kidney Disease & Comorbidities

Obesity frequently co-occurs with type 2 diabetes, chronic kidney disease, obstructive sleep apnea, and osteoarthritis. Oral obesity drugs that help patients lose weight also address these chronic diseases. Treating diabetes is a core indication for several GLP-1-based compounds, and the overlap between obesity medications and diabetes treatment has accelerated the development of oral formulations.

Oral Obesity Drugs for Treating Diabetes & Blood Sugar

Semaglutide was originally developed for treating diabetes before its obesity indication. Orforglipron has also shown blood sugar reduction in patients with type 2 diabetes. For patients with both obesity and diabetes, oral obesity drugs offer a dual benefit: clinically meaningful weight loss and improved glycaemic control. Treating diabetes with GLP-1-based obesity medications may reduce the need for insulin in some patients, simplifying overall chronic disease management.

Chronic Kidney Disease, Sleep Apnea & Osteoarthritis

Chronic kidney disease affects a substantial proportion of patients with obesity and diabetes. Clinical trials have begun evaluating GLP-1-based obesity medications for kidney-protective effects. Obstructive sleep apnea improves with weight loss, and tirzepatide recently received FDA approval for obesity-related obstructive sleep apnea—setting a precedent for oral obesity drugs. Osteoarthritis pain also improves with weight loss, as reduced body weight decreases mechanical load on weight-bearing joints. These other chronic diseases represent additional indications that could expand the market for oral obesity medications.

Daily Pill vs Weekly Injection — Dosing, Diet & Long-Term Management

The choice between a daily pill and a weekly injection involves trade-offs in convenience, efficacy, and adherence. Wegovy pill requires patients to take the tablet on an empty stomach with a small amount of water, then wait 30 minutes before eating—a constraint that orforglipron avoids as a non-peptide oral formulation. Weekly injection alternatives like injectable semaglutide or tirzepatide eliminate daily dosing but require self-injection. For patients seeking to improve weight loss outcomes, the choice depends on individual preferences, lifestyle, and clinical context.

Daily Pill vs Weekly Injection Convenience

A daily pill fits naturally into routines that already include other oral medications. However, the empty stomach requirement for peptide-based oral formulations like Wegovy pill can be inconvenient. New pills in development, such as orforglipron, eliminate food restrictions entirely. Weekly injection regimens require fewer doses but involve needle use. Patient surveys consistently show that many patients prefer oral obesity medications when efficacy is comparable—a preference that drives high demand for new oral formulations.

Reduced-Calorie Diet, Combined Strategy & Long-Term Management

All oral obesity drugs are indicated as adjuncts to a reduced-calorie diet and increased physical activity. Long-term management of obesity requires sustained treatment, as discontinuing obesity medications typically leads to weight regain. An approach that combines pharmacotherapy, behavioural counselling, strength training, and nutritional guidance offers the best prospect for durable weight loss. In early February 2026, several obesity medicine groups issued updated guidance emphasising long-term management strategies for patients on oral obesity medications and the importance of treating obesity as a chronic disease requiring ongoing other treatments beyond medication alone.